Diabetic Neuropathy - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 117
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D3E08F5A71DEN
Leaflet:

Download PDF Leaflet

Diabetic Neuropathy - Pipeline Review, H2 2016
Diabetic Neuropathy - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy – Pipeline Review, H2 2016, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 1, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.Diabetic Neuropathy.

Diabetic Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Neuropathy (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diabetic Neuropathy Overview
Therapeutics Development
Pipeline Products for Diabetic Neuropathy - Overview
Pipeline Products for Diabetic Neuropathy - Comparative Analysis
Diabetic Neuropathy - Therapeutics under Development by Companies
Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes
Diabetic Neuropathy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diabetic Neuropathy - Products under Development by Companies
Diabetic Neuropathy - Products under Investigation by Universities/Institutes
Diabetic Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics, Inc.
Araim Pharmaceuticals, Inc.
Celgene Corporation
Commence Bio, Inc.
Glucox Biotech AB
KPI Therapeutics, Inc.
Lpath, Inc.
Medifron DBT Co., Ltd.
Neuralstem, Inc.
NovaLead Pharma Pvt. Ltd.
Novartis AG
Omeros Corporation
PhiloGene, Inc.
Reata Pharmaceuticals, Inc.
Relief Therapeutics S.A.
Sucampo Pharmaceuticals, Inc.
ViroMed Co Ltd
Diabetic Neuropathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
atexakin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benfotiamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNV-222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cibinetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyndacel-M - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EMA-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDR-652 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLP-198 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSI-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSI-566 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-721 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pirenzepine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTA-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RTU-1096 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Diabetic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
U-2902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XK-568b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Neuropathy - Dormant Projects
Diabetic Neuropathy - Discontinued Products
Diabetic Neuropathy - Product Development Milestones
Featured News & Press Releases
Sep 08, 2016: ViroMed proceeding with the World’s first phase III gene therapy clinical trial for diabetic peripheral neuropathy
Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab
Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting
Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial
Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 117

LIST OF TABLES

Number of Products under Development for Diabetic Neuropathy, H2 2016
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Diabetic Neuropathy - Pipeline by Achelios Therapeutics, Inc., H2 2016
Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
Diabetic Neuropathy - Pipeline by Celgene Corporation, H2 2016
Diabetic Neuropathy - Pipeline by Commence Bio, Inc., H2 2016
Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H2 2016
Diabetic Neuropathy - Pipeline by KPI Therapeutics, Inc., H2 2016
Diabetic Neuropathy - Pipeline by Lpath, Inc., H2 2016
Diabetic Neuropathy - Pipeline by Medifron DBT Co., Ltd., H2 2016
Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H2 2016
Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016
Diabetic Neuropathy - Pipeline by Novartis AG, H2 2016
Diabetic Neuropathy - Pipeline by Omeros Corporation, H2 2016
Diabetic Neuropathy - Pipeline by PhiloGene, Inc., H2 2016
Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H2 2016
Diabetic Neuropathy - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diabetic Neuropathy - Dormant Projects, H2 2016
Diabetic Neuropathy - Dormant Projects (Contd..1), H2 2016
Diabetic Neuropathy - Dormant Projects (Contd..2), H2 2016
Diabetic Neuropathy - Dormant Projects (Contd..3), H2 2016
Diabetic Neuropathy - Discontinued Products, H2 2016 110

LIST OF FIGURES

Number of Products under Development for Diabetic Neuropathy, H2 2016
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Diabetic Nephropathy - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 220 pages

Ask Your Question

Diabetic Neuropathy - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: